MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12969-017-0212-y

Медицинская библиотека · Pediatric rheumatology online journal · 2017

Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.

Ruperto Nicolino, Brunner Hermine I, Zuber Zbigniew, Tzaribachev Nikolay, Kingsbury Daniel J, Foeldvari Ivan, Horneff Gerd, Smolewska Elzbieta, Vehe Richard K, Hazra Anasuya, Wang Rong, Mebus Charles A, Alvey Christine, Lamba Manisha, Krishnaswami Sriram, Stock Thomas C, Wang Min, Suehiro Ricardo, Martini Alberto, Lovell Daniel J, Pediatric Rheumatology International Trials Organization (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG)

Клиническое исследование I фазыСтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease and a leading cause of childhood disability. The objective of this study was to characterize the PK, safety, and taste acceptability of tofacitinib in patients with JIA.

METHODS

This Phase 1, open-label, multiple-dose (twice daily [BID] for 5 days) study of tofacitinib in patients with active (≥ 5 joints) polyarticular course JIA was conducted from March 2013-December 2015. Patients were allocated to one of three age-based cohorts: Cohort 1, 12 to < 18 years; Cohort 2, 6 to < 12 years; and Cohort 3, 2 to < 6 years. Tofacitinib was administered according to age and body weight as tablets or oral solution (grape flavor). PK were assessed on Day 5; safety was assessed at screening, Day 1, and Day 5. Taste acceptability of the oral solution was evaluated.

RESULTS

Twenty-six patients (age range 2-17 years) were enrolled: Cohort 1, N = 8; Cohort 2, N = 9; Cohort 3, N = 9; median tofacitinib doses were 5.0, 2.5, and 3.0 mg BID, respectively. The higher median tofacitinib dose in Cohort 3 versus Cohort 2 reflected implementation of an amended dosing scheme following an interim PK analysis after Cohort 2 recruitment. Geometric mean AUC at steady state (AUCtau) was 156.6 ng•h/mL in Cohort 1, 118.8 ng•h/mL in Cohort 2, and 142.5 ng•h/mL in Cohort 3; Cmax (ng/mL) was 47.0, 41.7, and 66.2, respectively. Ctrough, Cmin, and t1/2 were similar in Cohorts 2 and 3, but higher in Cohort 1. Median time to Cmax (Tmax) was similar between cohorts. Apparent clearance and volume of distribution decreased with decreasing age. Tofacitinib was well tolerated, with no serious adverse events or discontinuations due to adverse events reported. Taste acceptability was confirmed.

CONCLUSIONS

PK findings from this study in children with polyarticular course JIA established dosing regimens and acceptable taste for use in subsequent studies within the tofacitinib pediatric development program.

TRIAL REGISTRATION: ClinicalTrials.gov: NCT01513902 .

Для цитирования: Ruperto Nicolino, Brunner Hermine I, Zuber Zbigniew, Tzaribachev Nikolay, Kingsbury Daniel J, Foeldvari Ivan, Horneff Gerd, Smolewska Elzbieta, Vehe Richard K, Hazra Anasuya, Wang Rong, Mebus Charles A, Alvey Christine, Lamba Manisha, Krishnaswami Sriram, Stock Thomas C, Wang Min, Suehiro Ricardo, Martini Alberto, Lovell Daniel J, Pediatric Rheumatology International Trials Organization (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG). Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.. Pediatric rheumatology online journal. 2017. DOI: 10.1186/s12969-017-0212-y.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.